NCT05165407View on ClinicalTrials.gov

Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 12, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Neuroendocrine Neoplasm
Interventions
DRUG

Sintilimab

Sintilimab 200mg will be intravenously administered on Day 1 of each cycle

DRUG

IBI310

IBI310 1mg/kg be intravenously administered on Day 1 of every 2 cycle

DRUG

Surufatinib

Surufatinib 250mg will be taken orally once daily continuously

Trial Locations (2)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

RECRUITING

Bejing cancer hospital, Beijing

All Listed Sponsors
lead

Peking University

OTHER